Drug Discovery · Cambridge, MA · Founded 2020 · Privately Held (backing)
Operator of a clinical-stage biotechnology company intended to explore the full potential of alpha-emitting radioantibodies to treat cancer. Convergent Therapeutics is based in Cambridge, MA and was founded in 2020. Its last known valuation is $280 million. It has raised $130 million across 2 recorded rounds; the latest was a $22.2 million early-stage round in Jul 2024.
Last price · $/share
—
Implied valuation
$280.0M
Total raised
$130.0M
Last round
Early Stage VC
Jul 2024
Cap table — not yet on record
Convergent Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Convergent Therapeutics with a free account
·Watch Convergent Therapeutics: the Monday email on marks, rounds and moves
Where does Convergent Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Convergent Therapeutics's 2 recorded funding rounds.
